Franziska Kluwe

Franziska Kluwe

Auto-generated profile, based on publicly available information

Franziska Kluwe

Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2019 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
JSJosefine Schulz
Josefine Schulz
FKFranziska Kluwe
Franziska Kluwe
GMGerd Mikus
Gerd Mikus
Robin MicheletRobin Michelet
Robin Michelet
CKCharlotte Kloft
Charlotte Kloft
Voriconazole, a second-generation triazole frequently used for the prophylaxis and treatment of invasive fungal infections, undergoes complex metabolism mainly involving various (polymorphic) cytochrome P450 enzymes in humans. Although high inter- and intraindividual variability in voriconazole pharmacokinetics have been observed and the therapeutic range for this compound is relatively narrow, the metabolism of voriconazole has not been fully elucidated yet. The available literature data investigating the multiple different pathways and metabolites are extremely unbalanced and thus the absolute or relative contribution of the different pathways and enzymes involved in the metabolism of voriconazole remains uncertain. Furthermore, other factors such as nonlinear pharmacokinetics caused by auto-inhibition or -induction and polymorphisms of the metabolizing enzymes hinder safe and effective voriconazole dosing in clinical practice and have not yet been studied sufficiently. This review aimed at amalgamating the available literature on the pharmacokinetics of voriconazole in vitro and in vivo, with a special focus on metabolism in adults and children, in order to congregate an overall landscape of the current body of knowledge and identify knowledge gaps, opening the way towards further research in order to foster the understanding, towards better therapeutic dosing decisions.

17 October 2020 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
FKFranziska Kluwe
Franziska Kluwe
Robin MicheletRobin Michelet
Robin Michelet
AMAnna Mueller‐Schoell
Anna Mueller‐Schoell
CMCorinna Maier
Corinna Maier
LKLena Klopp‐Schulze
Lena Klopp‐Schulze
CKCharlotte Kloft
Charlotte Kloft
Click on the article title to read more.

1 April 2019 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
CKClaudia Kirbs
Claudia Kirbs
FKFranziska Kluwe
Franziska Kluwe
FDFranziska Drescher
Franziska Drescher
ELEdith Lackner
Edith Lackner
PMPeter Matzneller
Peter Matzneller
CKCharlotte Kloft
Charlotte Kloft

21 August 2023 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
PDF file
FKFranziska Kluwe
Franziska Kluwe
Robin MicheletRobin Michelet
Robin Michelet
WHWilhelm Huisinga
Wilhelm Huisinga
Markus ZeitlingerMarkus Zeitlinger
Markus Zeitlinger
GMGerd Mikus
Gerd Mikus
CKCharlotte Kloft
Charlotte Kloft
Background and Objectives Model-informed precision dosing (MIPD) frequently uses nonlinear mixed-effects (NLME) models to predict and optimize therapy outcomes based on patient characteristics and therapeutic drug monitoring data. MIPD is indicated for compounds with narrow therapeutic range and complex pharmacokinetics (PK), such as voriconazole, a broad-spectrum antifungal drug for prevention and treatment of invasive fungal infections. To provide guidance and recommendations for evidence-based application of MIPD for voriconazole, this work aimed to (i) externally evaluate and compare the predictive performance of a published so-called ‘hybrid’ model for MIPD (an aggregate model comprising features and prior information from six previously published NLME models) versus two ‘standard’ NLME models of voriconazole, and (ii) investigate strategies and illustrate the clinical impact of Bayesian forecasting for voriconazole. Methods A workflow for external evaluation and application of MIPD for voriconazole was implemented. Published voriconazole NLME models were externally evaluated using a comprehensive in-house clinical database comprising nine voriconazole studies and prediction-/simulation-based diagnostics. The NLME models were applied using different Bayesian forecasting strategies to assess the influence of prior observations on model predictivity. Results The overall best predictive performance was obtained using the aggregate model. However, all NLME models showed only modest predictive performance, suggesting that (i) important PK processes were not sufficiently implemented in the structural submodels, (ii) sources of interindividual variability were not entirely captured, and (iii) interoccasion variability was not adequately accounted for. Predictive performance substantially improved by including the most recent voriconazole observations in MIPD. Conclusion Our results highlight the potential clinical impact of MIPD for voriconazole and indicate the need for a comprehensive (pre-)clinical database as basis for model development and careful external model evaluation for compounds with complex PK before their successful use in MIPD.

30 October 2024 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
PDF file
ASAyatallah Saleh
Ayatallah Saleh
JSJosefine Schulz
Josefine Schulz
JSJan-Frederik Schlender
Jan-Frederik Schlender
LALinda B. S. Aulin
Linda B. S. Aulin
AKAmrei-Pauline Konrad
Amrei-Pauline Konrad
Robin MicheletRobin Michelet
Robin Michelet
Background and Objective Voriconazole (VRC), a broad-spectrum antifungal drug, exhibits nonlinear pharmacokinetics (PK) due to saturable metabolic processes, autoinhibition and metabolite-mediated inhibition on their own formation. VRC PK is also characterised by high inter- and intraindividual variability, primarily associated with cytochrome P450 (CYP) 2C19 genetic polymorphism. Additionally, recent in vitro findings indicate that VRC main metabolites, voriconazole N-oxide (NO) and hydroxyvoriconazole (OHVRC), inhibit CYP enzymes responsible for VRC metabolism, adding to its PK variability. This variability poses a significant risk of therapeutic failure or adverse events, which are major challenges in VRC therapy. Understanding the underlying processes and sources of these variabilities is essential for safe and effective therapy. This work aimed to develop a whole-body physiologically-based pharmacokinetic (PBPK) modelling framework that elucidates the complex metabolism of VRC and the impact of its metabolites, NO and OHVRC, on the PK of the parent, leveraging both in vitro and in vivo clinical data in a middle-out approach. Methods A coupled parent-metabolite PBPK model for VRC, NO and OHVRC was developed in a stepwise manner using PK-Sim® and MoBi®. Based on available in vitro data, NO formation was assumed to be mediated by CYP2C19, CYP3A4, and CYP2C9, while OHVRC formation was attributed solely to CYP3A4. Both metabolites were assumed to be excreted via renal clearance, with hepatic elimination also considered for NO. Inhibition functions were implemented to describe the complex interaction network of VRC autoinhibition and metabolite-mediated inhibition on each CYP enzyme. Results Using a combined bottom-up and middle-out approach, incorporating data from multiple clinical studies and existing literature, the model accurately predicted plasma concentration-time profiles across various intravenous dosing regimens in healthy adults, of different CYP2C19 genotype-predicted phenotypes. All (100%) of the predicted area under the concentration–time curve (AUC) and 94% of maximum concentration (Cmax) values of VRC met the 1.25-fold acceptance criterion, with overall absolute average fold errors of 1.12 and 1.14, respectively. Furthermore, all predicted AUC and Cmax values of NO and OHVRC met the twofold acceptance criterion. Conclusion This comprehensive parent-metabolite PBPK model of VRC quantitatively elucidated the complex metabolism of the drug and emphasised the substantial impact of the primary metabolites on VRC PK. The comprehensive approach combining bottom-up and middle-out modelling, thereby accounting for VRC autoinhibition, metabolite-mediated inhibition, and the impact of CYP2C19 genetic polymorphisms, enhances our understanding of VRC PK. Moreover, the model can be pivotal in designing further in vitro experiments, ultimately allowing for extrapolation to paediatric populations, enhance treatment individualisation and improve clinical outcomes.